Rxsight
NASDAQ: RXSTPasadena, US · Incorporated in Delaware · 9 known investors
Find your way into Rxsight
RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed. The company's monofocal lens targets cataract surgery and vision correction, including astigmatism as low as 0.50 D.
Founders & leadership
RH
Robert H. GrubbsCo-founder
DM
Daniel M. SchwartzCo-founder
DV
D. Verne SharmaExecutive
RD
Richard DrinkwardinExecutive
RK
Ron KurtzPresident, Chief Executive Officer & Director
MW
Mark WilterdinginChief Financial Officer
EW
Eric WeinberginChief Business Development Officer
IG
Ilya GoldshlegerinChief Operating Officer
SG
Scott GainesinChief Customer OfficerHe previously founded and led Systemize Partners, a consulting firm focused on commercialization and operations scaling, and has held leadership roles in commercial and manufacturing operations across medical device companies including TriVascular, Endologix, SI-BONE, and Penumbra.
Board
JP
Javier Perez-SalaBoard director
JB
Jan BonelBoard director
JD
Joseph DevivoBoard director
Investors · 9
Reported raises · per SEC filings
Form D private placements$62.7M disclosed across 2 rounds · 2012–2017
▶$50MraisedApr 2017 · 62 investors · Other Health CareRule 506(b)
▶$50MraisedApr 2017 · 62 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- William LinkDirector
- Juliet BakkerDirector
- J. Andy CorleyDirector
- Shelley ThunenExecutive Officer
- Ron KurtzExecutive Officer, Director
- Dan SchwartzDirector
- Bruce RobertsonDirector
- Chris CoxDirector
- Werner WolfenDirector
- Offering amount
- $77.5M
- Amount sold
- $50M
- First sale
- Feb 2017
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$12.7MraisedMar 2014 · 45 investors · Other TechnologyRule 506(b)
▶$12.7MraisedMar 2014 · 45 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph DevivoDirector
- James N. AdlerDirector
- Robert H. GrubbsDirector
- Werner F. WolfenDirector
- D. Verne SharmaExecutive Officer, Director
- Javier Perez-SalaDirector
- Richard DrinkwardExecutive Officer
- Jan BonelDirector
- Daniel M. SchwartzDirector
- Offering amount
- $47M
- Amount sold
- $12.7M
- Minimum investment
- $50K
- Sales commissions
- $450K
- Proceeds to insiders
- $467.5K
- Placement agents
- Piper Jaffray & Co., Brockett Tamny & Co., Incorporated
- First sale
- Oct 2012
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$424.8Mvaluation at IPOJul 2021 · $16.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Rxsight do?
- RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed. The company's monofocal lens targets cataract surgery and vision correction, including astigmatism as low as 0.50 D.
- Who founded Rxsight?
- Rxsight was founded by Robert H. Grubbs, Daniel M. Schwartz.
- Who are Rxsight's investors?
- Rxsight's investors include Flying L Partners, Foresite Capital, H.I.G. Capital, H.I.G. HealthBridge Partners, Longitude Capital, RA Capital, Visionary Ventures, RxSight and 1 more.
- How much funding has Rxsight raised?
- Rxsight has disclosed $62.7M raised across 2 rounds.
- Where is Rxsight headquartered?
- Rxsight is headquartered in Pasadena, US.